Interim Trial Results Of Russia's COVID Vaccine 'Sputnik V' Score 92% Efficacy

According to the interim trials, Russian COVID-19 vaccine, Sputnik V, has shown a 92% efficacy against the coronavirus. The human adenovirus vaccine uses a weakened and genetically modified virus to build an immune response. However, the mid-stage trials, which are yet to be peer-reviewed, were conducted on a small population of 16,000 participants. In India, the vaccine is being tested by Dr Reddy's Laboratories in association with the Russian Direct Investment Fund.